Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
- PMID: 36472543
- PMCID: PMC10081723
- DOI: 10.1089/dia.2022.0421
Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
Abstract
Objective: To evaluate safety and effectiveness of MiniMed™ 670G hybrid closed loop (HCL) in comparison with continuous subcutaneous insulin infusion (CSII) therapy for 6 months in persons with type 1 diabetes (T1D). Methods: Adults (aged 18-80 years), adolescents, and children (aged 2-17 years) with T1D who were using CSII therapy were enrolled and randomized (1:1) to 6 months of HCL intervention (n = 151, mean age of 39.9 ± 19.8 years) or CSII without continuous glucose monitoring (n = 151, 35.7 ± 18.4 years). Primary effectiveness endpoints included change in A1C for Group 1 (baseline A1C >8.0%), from baseline to the end of study, and difference in the end of study percentage of time spent below 70 mg/dL (%TBR <70 mg/dL) for Group 2 (baseline A1C ≤8.0%), to show superiority of HCL intervention versus control. Secondary effectiveness endpoints were change in A1C and %TBR <70 mg/dL for Group 2 and Group 1, respectively, to show noninferiority of HCL intervention versus control. Primary safety endpoints were rates of severe hypoglycemia and diabetic ketoacidosis (DKA). Results: Change in A1C and difference in %TBR <70 mg/dL for the overall group were significantly improved, in favor of HCL intervention. In addition, a significant mean (95% confidence interval) change in A1C was observed for both Group 1 (-0.8% [-1.1% to -0.4%], P < 0.0001) and Group 2 (-0.3% [-0.5% to -0.1%], P < 0.0001), in favor of HCL intervention. The same was observed for difference in %TBR <70 mg/dL for Group 1 (-2.2% [-3.6% to -0.9%]) and Group 2 (-4.9% [-6.3% to -3.6%]) (P < 0.0001 for both). There was one DKA event during run-in and six severe hypoglycemic events: two during run-in and four during study (HCL: n = 0 and CSII: n = 4 [6.08 per 100 patient-years]). Conclusions: This RCT demonstrates that the MiniMed 670G HCL safely and significantly improved A1C and %TBR <70 mg/dL compared with CSII control in persons with T1D, irrespective of baseline A1C level.
Keywords: A1C; Adult; Diabetes treatment satisfaction; Hybrid closed loop; Pediatric; Time below range; Time in range; Type 1 diabetes.
Conflict of interest statement
All principal investigator authors received research support from Medtronic to conduct the clinical trial at their respective investigational site. A.K., C.L., B.M., T.L.C., J.S., S.W.L., A.S.R., and R.A.V. are or were employees of Medtronic.
Figures
Similar articles
-
Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.Diabetes Technol Ther. 2023 Nov;25(11):755-764. doi: 10.1089/dia.2023.0255. Epub 2023 Oct 25. Diabetes Technol Ther. 2023. PMID: 37782145 Clinical Trial.
-
Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.Eur J Pediatr. 2023 May;182(5):1949-1963. doi: 10.1007/s00431-023-04833-4. Epub 2023 Feb 21. Eur J Pediatr. 2023. PMID: 36809498 Free PMC article. Review.
-
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.Diabetes Technol Ther. 2022 Mar;24(3):178-189. doi: 10.1089/dia.2021.0319. Epub 2021 Nov 16. Diabetes Technol Ther. 2022. PMID: 34694909 Free PMC article.
-
Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.Diabetes Technol Ther. 2019 Mar;21(3):110-118. doi: 10.1089/dia.2018.0328. Epub 2019 Feb 20. Diabetes Technol Ther. 2019. PMID: 30785311
-
Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.Ann Intern Med. 2012 Sep 4;157(5):336-47. doi: 10.7326/0003-4819-157-5-201209040-00508. Ann Intern Med. 2012. PMID: 22777524 Review.
Cited by
-
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. Diabetes Care. 2024. PMID: 38078590 Review.
-
Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-analysis of Outpatient Randomized Controlled Trials.Diabetes Care. 2023 Dec 1;46(12):2300-2307. doi: 10.2337/dc23-0504. Diabetes Care. 2023. PMID: 38011519 Free PMC article. Review.
-
Efficacy of automated insulin delivery (AID) systems in type 1 diabetes: protocol of a systematic review and network meta-analysis of outpatient randomised controlled trials.BMJ Open. 2023 Oct 10;13(10):e074317. doi: 10.1136/bmjopen-2023-074317. BMJ Open. 2023. PMID: 37816564 Free PMC article.
-
Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.Commun Med (Lond). 2023 Oct 5;3(1):132. doi: 10.1038/s43856-023-00358-x. Commun Med (Lond). 2023. PMID: 37794113 Free PMC article.
-
Glucose control and psychosocial outcomes with use of automated insulin delivery for 12 to 96 weeks in type 1 diabetes: a meta-analysis of randomised controlled trials.Diabetol Metab Syndr. 2023 Sep 28;15(1):190. doi: 10.1186/s13098-023-01144-4. Diabetol Metab Syndr. 2023. PMID: 37759290 Free PMC article. Review.
References
-
- Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986. - PubMed
-
- White NH, Cleary PA, Dahms W, et al. : Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001;139:804–812. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical